FDA Brief

Warning letters Drugs

FDA warning letter to

Kin Meds

LowIssued Feb 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.

What happened

FDA reviewed Kin Meds' website at https://kinmeds.com in December 2025 and observed that it offers compounded semaglutide and tirzepatide drug products. The letter says the pictured labels show “Kin Meds” as if it were the compounder, although FDA states it is not. FDA also cited website claims that the products have the “Same Active Ingredient as common brands” and can help hit weight management goals at a fraction of the cost, which imply FDA approval or evaluation that compounded drugs do not have.

What FDA found

  1. The website’s pictured labels name “Kin Meds” as the compounder even though FDA says Kin Meds is not the compounder, so the labeling is false or misleading.

    FDCA § 502(a), 21 U.S.C. § 352(a); 21 CFR § 201.1(h)(2)
  2. The website’s advertising or promotion is false or misleading because it presents Kin Meds as the compounder of the compounded semaglutide and tirzepatide products.

    FDCA § 502(bb), 21 U.S.C. § 352(bb)
  3. The claim “Same Active Ingredient as common brands” implies FDA approval or evaluation even though compounded drugs are not FDA-approved, making the products misbranded.

    FDCA §§ 502(a), 502(bb), 21 U.S.C. §§ 352(a), 352(bb)
  4. The claim about hitting weight management goals with the same ingredient as brand-name GLP-1 drugs at a fraction of the cost implies FDA approval or evaluation even though compounded drugs are not FDA-approved.

    FDCA §§ 502(a), 502(bb), 21 U.S.C. §§ 352(a), 352(bb)
  5. The misbranded compounded semaglutide and tirzepatide products were introduced or delivered for introduction into interstate commerce.

    FDCA § 301(a), 21 U.S.C. § 331(a)
  6. Receiving misbranded drugs in interstate commerce, or delivering or offering to deliver them, is also prohibited.

    FDCA § 301(c), 21 U.S.C. § 331(c)

What FDA wants

FDA asks Kin Meds to respond in writing within 15 working days to CDER’s Office of Compounding Quality and Compliance with specific steps taken to address the violations, including identifying the entities that produce the products, providing sample labeling, and addressing or modifying the website claims.

Who should pay attention

  • telehealth companies selling compounded GLP-1 drugs
  • compounders whose products are advertised by telehealth sites
  • marketing and compliance teams for online drug sellers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low